{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:29:21Z","timestamp":1791304161398,"version":"4.3.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"8101","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Marburg virus (MARV) is a filovirus that causes severe and often lethal haemorrhagic fever\n                    <jats:sup>1,2<\/jats:sup>\n                    . Despite the increasing frequency of MARV outbreaks, no vaccines or therapeutics are licensed for use in humans. Here we designed mutations that improve the expression, thermostability and immunogenicity of the prefusion MARV glycoprotein (GP) ectodomain trimer, which is the sole target of neutralizing antibodies and vaccines in development\n                    <jats:sup>3\u20138<\/jats:sup>\n                    . We discovered a fully human, pan-marburgvirus monoclonal antibody, MARV16, that broadly neutralizes all MARV isolates, Ravn virus and Dehong virus with 40\u2013100-fold increased potency relative to previously described antibodies\n                    <jats:sup>9<\/jats:sup>\n                    . Moreover, MARV16 provided therapeutic protection in guinea pigs challenged with MARV. We determined a cryogenic electron microscopy structure of MARV16-bound MARV GP. The structure shows that MARV16 recognizes a prefusion-specific epitope spanning GP1 and GP2, which blocks receptor binding and prevents conformational changes required for viral entry. We further determined the architecture of the MARV GP glycan cap, which shields the receptor-binding site, and identified architectural similarities with distantly related filovirus GPs. MARV16 and previously identified antibodies directed against the receptor-binding site\n                    <jats:sup>9\u201311<\/jats:sup>\n                    simultaneously bound MARV GP. These antibody cocktails required multiple mutations to escape neutralization by both antibodies, a result that paves the way for the development of MARV therapeutics resistant to viral evolution. MARV GP stabilization along with the discovery of MARV16 advance prevention and treatment options for MARV disease.\n                  <\/jats:p>","DOI":"10.1038\/s41586-025-09868-1","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:28:42Z","timestamp":1763047722000},"page":"459-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potent neutralization of Marburg virus by a vaccine-elicited antibody"],"prefix":"10.1038","volume":"650","author":[{"given":"Amin","family":"Addetia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Perruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-2226","authenticated-orcid":false,"given":"Kaitlin","family":"Sprouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-6949","authenticated-orcid":false,"given":"Young-Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-8330","authenticated-orcid":false,"given":"Matthew","family":"McCallum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-6256","authenticated-orcid":false,"given":"Cameron","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Partini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-0018","authenticated-orcid":false,"given":"Katja","family":"Culap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Balmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagata","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Alfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenny","family":"Goez-Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7046-7683","authenticated-orcid":false,"suffix":"Jr","given":"Ricardo","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-1364","authenticated-orcid":false,"given":"Davide","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-8675","authenticated-orcid":false,"given":"David","family":"Veesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"9868_CR1","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1086\/520551","volume":"196","author":"W Slenczka","year":"2007","unstructured":"Slenczka, W. & Klenk, H. D. Forty years of Marburg virus. J. Infect. Dis. 196, S131\u2013S135 (2007).","journal-title":"J. Infect. Dis."},{"key":"9868_CR2","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3390\/v4101878","volume":"4","author":"K Brauburger","year":"2012","unstructured":"Brauburger, K., Hume, A. J., M\u00fchlberger, E. & Olejnik, J. Forty-five years of Marburg virus research. Viruses 4, 1878\u20131927 (2012).","journal-title":"Viruses"},{"key":"9868_CR3","doi-asserted-by":"publisher","first-page":"eabq6364","DOI":"10.1126\/scitranslmed.abq6364","volume":"14","author":"R Hunegnaw","year":"2022","unstructured":"Hunegnaw, R. et al. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. Sci. Transl. Med. 14, eabq6364 (2022).","journal-title":"Sci. Transl. Med."},{"key":"9868_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","volume":"401","author":"MJ Hamer","year":"2023","unstructured":"Hamer, M. J. et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 401, 294\u2013302 (2023).","journal-title":"Lancet"},{"key":"9868_CR5","doi-asserted-by":"publisher","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","volume":"13","author":"B Callendret","year":"2018","unstructured":"Callendret, B. et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS ONE 13, e0192312 (2018).","journal-title":"PLoS ONE"},{"key":"9868_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 21, 493\u2013506 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"9868_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/infdis\/jiu511","volume":"211","author":"UN Sarwar","year":"2015","unstructured":"Sarwar, U. N. et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J. Infect. Dis. 211, 549\u2013557 (2015).","journal-title":"J. Infect. Dis."},{"key":"9868_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(24)02241-4","volume":"404","author":"P Adepoju","year":"2024","unstructured":"Adepoju, P. Rwandan Marburg outbreak sparks vaccine efforts. Lancet 404, 1389 (2024).","journal-title":"Lancet"},{"key":"9868_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"9868_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","volume":"160","author":"T Hashiguchi","year":"2015","unstructured":"Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904\u2013912 (2015).","journal-title":"Cell"},{"key":"9868_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","volume":"23","author":"LB King","year":"2018","unstructured":"King, L. B. et al. The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23, 101\u2013109 (2018).","journal-title":"Cell Host Microbe"},{"key":"9868_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2045-6","volume":"16","author":"L Nyakarahuka","year":"2016","unstructured":"Nyakarahuka, L. et al. How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence. BMC Infect. Dis. 16, 708 (2016).","journal-title":"BMC Infect. Dis."},{"key":"9868_CR13","doi-asserted-by":"publisher","first-page":"e0309762","DOI":"10.1371\/journal.pone.0309762","volume":"19","author":"V Mmbaga","year":"2024","unstructured":"Mmbaga, V. et al. Epidemiological description of Marburg virus disease outbreak in Kagera region, Northwestern Tanzania. PLoS ONE 19, e0309762 (2024).","journal-title":"PLoS ONE"},{"key":"9868_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104377","volume":"81","author":"J Wellington","year":"2022","unstructured":"Wellington, J. et al. Marburg virus outbreak in Ghana: an impending crisis. Ann. Med. Surg. 81, 104377 (2022).","journal-title":"Ann. Med. Surg."},{"key":"9868_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1056\/NEJMc2313181","volume":"391","author":"L Fontana","year":"2024","unstructured":"Fontana, L. et al. Case series of patients with Marburg virus disease, Equatorial Guinea, 2023. N. Engl. J. Med. 391, 283\u2013285 (2024).","journal-title":"N. Engl. J. Med."},{"key":"9868_CR16","doi-asserted-by":"publisher","first-page":"101121","DOI":"10.1016\/j.lanmic.2025.101121","volume":"6","author":"P Venkatesan","year":"2025","unstructured":"Venkatesan, P. Marburg virus outbreak in Tanzania. Lancet Microbe 6, 101121 (2025).","journal-title":"Lancet Microbe"},{"key":"9868_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nature19790","volume":"538","author":"EC Holmes","year":"2016","unstructured":"Holmes, E. C., Dudas, G., Rambaut, A. & Andersen, K. G. The evolution of Ebola virus: insights from the 2013\u20132016 epidemic. Nature 538, 193\u2013200 (2016).","journal-title":"Nature"},{"key":"9868_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2016.10.014","volume":"167","author":"WE Diehl","year":"2016","unstructured":"Diehl, W. E. et al. Ebola virus glycoprotein with increased infectivity dominated the 2013\u20132016 epidemic. Cell 167, 1088\u20131098 (2016).","journal-title":"Cell"},{"key":"9868_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"9868_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"9868_CR21","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1086\/520591","volume":"196","author":"SM Jones","year":"2007","unstructured":"Jones, S. M. et al. Assessment of a vesicular stomatitis virus\u2013based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J. Infect. Dis. 196, S404\u2013S412 (2007).","journal-title":"J. Infect. Dis."},{"key":"9868_CR22","doi-asserted-by":"publisher","first-page":"2327747","DOI":"10.1080\/21645515.2024.2327747","volume":"20","author":"N Goldstein","year":"2024","unstructured":"Goldstein, N. et al. Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: a phase 3, randomized, double-blind, placebo-controlled trial. Hum. Vaccines Immunother. 20, 2327747 (2024).","journal-title":"Hum. Vaccines Immunother."},{"key":"9868_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0042-6822(91)90680-A","volume":"182","author":"H Feldmann","year":"1991","unstructured":"Feldmann, H., Will, C., Schikore, M., Slenczka, W. & Klenk, H.-D. Glycosylation and oligomerization of the spike protein of Marburg virus. Virology 182, 353\u2013356 (1991).","journal-title":"Virology"},{"key":"9868_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","volume":"477","author":"JE Carette","year":"2011","unstructured":"Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann\u2013Pick C1. Nature 477, 340\u2013343 (2011).","journal-title":"Nature"},{"key":"9868_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/viro.1999.0110","volume":"268","author":"VE Volchkov","year":"2000","unstructured":"Volchkov, V. E. et al. Proteolytic processing of Marburg virus glycoprotein. Virology 268, 1\u20136 (2000).","journal-title":"Virology"},{"key":"9868_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cell.2015.12.044","volume":"164","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann\u2013Pick C1. Cell 164, 258\u2013268 (2016).","journal-title":"Cell"},{"key":"9868_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"9868_CR28","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nsmb.2150","volume":"18","author":"JM Dias","year":"2011","unstructured":"Dias, J. M. et al. A shared structural solution for neutralizing Ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424\u20131427 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"9868_CR29","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1021\/bi3000353","volume":"51","author":"JS Harrison","year":"2012","unstructured":"Harrison, J. S., Koellhoffer, J. F., Chandran, K. & Lai, J. R. Marburg Virus glycoprotein GP2: pH-dependent stability of the ectodomain \u03b1-helical bundle. Biochemistry 51, 2515\u20132525 (2012).","journal-title":"Biochemistry"},{"key":"9868_CR30","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1021\/bi300976m","volume":"51","author":"JF Koellhoffer","year":"2012","unstructured":"Koellhoffer, J. F. et al. Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Biochemistry 51, 7665\u20137675 (2012).","journal-title":"Biochemistry"},{"key":"9868_CR31","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1093\/infdis\/jiv030","volume":"212","author":"N Liu","year":"2015","unstructured":"Liu, N., Tao, Y., Brenowitz, M. D., Girvin, M. E. & Lai, J. R. Structural and functional studies on the Marburg virus GP2 fusion loop. J. Infect. Dis. 212, S146\u2013S153 (2015).","journal-title":"J. Infect. Dis."},{"key":"9868_CR32","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9868_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"9868_CR34","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1016\/j.celrep.2020.03.025","volume":"30","author":"L Rutten","year":"2020","unstructured":"Rutten, L. et al. Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell Rep. 30, 4540\u20134550 (2020).","journal-title":"Cell Rep."},{"key":"9868_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22867-w","volume":"12","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat. Commun. 12, 2633 (2021).","journal-title":"Nat. Commun."},{"key":"9868_CR36","doi-asserted-by":"publisher","first-page":"e1005016","DOI":"10.1371\/journal.ppat.1005016","volume":"11","author":"ML Fusco","year":"2015","unstructured":"Fusco, M. L. et al. Protective mAbs and cross-reactive mAbs raised by immunization with engineered Marburg virus GPs. PLoS Pathog. 11, e1005016 (2015).","journal-title":"PLoS Pathog."},{"key":"9868_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","volume":"27","author":"pa ilinykh","year":"2020","unstructured":"ilinykh, p. a. et al. non-neutralizing antibodies from a marburg infection survivor mediate protection by Fc\u2013effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe 27, 976\u2013991 (2020).","journal-title":"Cell Host Microbe"},{"key":"9868_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00155-24","volume":"98","author":"BM Janus","year":"2024","unstructured":"Janus, B. M. et al. Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization. J. Virol. 98, e0015524 (2024).","journal-title":"J. Virol."},{"key":"9868_CR39","doi-asserted-by":"publisher","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","volume":"9","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. 9, eaai8711 (2017).","journal-title":"Sci. Transl. Med."},{"key":"9868_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).","journal-title":"Nat. Commun."},{"key":"9868_CR41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","volume":"174","author":"EO Saphire","year":"2018","unstructured":"Saphire, E. O. et al. Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell 174, 938\u2013952 (2018).","journal-title":"Cell"},{"key":"9868_CR42","doi-asserted-by":"crossref","unstructured":"Meyer, M. et al. Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses. Nat. Commun. 16, 5702 (2025).","DOI":"10.1038\/s41467-025-60057-0"},{"key":"9868_CR43","doi-asserted-by":"publisher","first-page":"e2314990121","DOI":"10.1073\/pnas.2314990121","volume":"121","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Structure and design of Langya virus glycoprotein antigens. Proc. Natl Acad. Sci. 121, e2314990121 (2024).","journal-title":"Proc. Natl Acad. Sci."},{"key":"9868_CR44","doi-asserted-by":"publisher","unstructured":"McCallum, M. & Veesler, D. Computational design of prefusion-stabilized Herpesvirus gB trimers. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.10.23.619923 (2024).","DOI":"10.1101\/2024.10.23.619923"},{"key":"9868_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning\u2013based protein sequence design using ProteinMPNN. Science 378, 49\u201356 (2022).","journal-title":"Science"},{"key":"9868_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01865-18","volume":"93","author":"R Keshwara","year":"2019","unstructured":"Keshwara, R. et al. A recombinant rabies virus expressing the Marburg Virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model. J. Virol. 93, e01865-18 (2019).","journal-title":"J. Virol."},{"key":"9868_CR47","doi-asserted-by":"publisher","unstructured":"Brunette, N. et al. A multivalent pan-ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by adapted Zaire and Sudan viruses. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.01.29.635581 (2025).","DOI":"10.1101\/2025.01.29.635581"},{"key":"9868_CR48","doi-asserted-by":"publisher","first-page":"e2316960121","DOI":"10.1073\/pnas.2316960121","volume":"121","author":"D Xu","year":"2024","unstructured":"Xu, D. et al. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc. Natl Acad. Sci. USA 121, e2316960121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9868_CR49","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382 (2020).","journal-title":"Cell"},{"key":"9868_CR50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/infdis\/jix592","volume":"217","author":"M Meyer","year":"2018","unstructured":"Meyer, M. et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217, 451\u2013455 (2018).","journal-title":"J. Infect. Dis."},{"key":"9868_CR51","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1128\/JVI.80.8.4174-4178.2006","volume":"80","author":"K Schornberg","year":"2006","unstructured":"Schornberg, K. et al. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80, 4174\u20134178 (2006).","journal-title":"J. Virol."},{"key":"9868_CR52","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41594-019-0191-4","volume":"26","author":"BR West","year":"2019","unstructured":"West, B. R. et al. Structural basis of broad Ebolavirus neutralization by a human survivor antibody. Nat. Struct. Mol. Biol. 26, 204\u2013212 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"9868_CR53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","volume":"49","author":"P Gilchuk","year":"2018","unstructured":"Gilchuk, P. et al. Multifunctional pan-Ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein. Immunity 49, 363\u2013374 (2018).","journal-title":"Immunity"},{"key":"9868_CR54","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1016\/j.cell.2021.09.035","volume":"184","author":"P Gilchuk","year":"2021","unstructured":"Gilchuk, P. et al. Pan-Ebolavirus protective therapy by two multifunctional human antibodies. Cell 184, 5593\u20135607 (2021).","journal-title":"Cell"},{"key":"9868_CR55","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.01.001","volume":"52","author":"P Gilchuk","year":"2020","unstructured":"Gilchuk, P. et al. Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad Ebolavirus neutralization. Immunity 52, 388\u2013403 (2020).","journal-title":"Immunity"},{"key":"9868_CR56","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.cell.2016.05.022","volume":"165","author":"x gong","year":"2016","unstructured":"gong, x. et al. structural insights into the niemann\u2013pick c1 (npc1)-mediated cholesterol transfer and Ebola infection. Cell 165, 1467\u20131478 (2016).","journal-title":"Cell"},{"key":"9868_CR57","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014\u20131018 (2020).","journal-title":"Science"},{"key":"9868_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT\u2013PCR and expression vector cloning. J. Immunol. Methods 329, 112\u2013124 (2008).","journal-title":"J. Immunol. Methods"},{"key":"9868_CR59","doi-asserted-by":"publisher","first-page":"W503","DOI":"10.1093\/nar\/gkn316","volume":"36","author":"X Brochet","year":"2008","unstructured":"Brochet, X., Lefranc, M.-P. & Giudicelli, V. IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503\u2013W508 (2008).","journal-title":"Nucleic Acids Res."},{"key":"9868_CR60","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1126\/science.abq0203","volume":"377","author":"JE Bowen","year":"2022","unstructured":"Bowen, J. E. et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 377, 890\u2013894 (2022).","journal-title":"Science"},{"key":"9868_CR61","doi-asserted-by":"publisher","first-page":"114530","DOI":"10.1016\/j.celrep.2024.114530","volume":"43","author":"A Addetia","year":"2024","unstructured":"Addetia, A. et al. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans. Cell Rep. 43, 114530 (2024).","journal-title":"Cell Rep."},{"key":"9868_CR62","doi-asserted-by":"publisher","first-page":"112621","DOI":"10.1016\/j.celrep.2023.112621","volume":"42","author":"A Addetia","year":"2023","unstructured":"Addetia, A. et al. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. Cell Rep. 42, 112621 (2023).","journal-title":"Cell Rep."},{"key":"9868_CR63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","volume":"621","author":"A Addetia","year":"2023","unstructured":"Addetia, A. et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature 621, 592\u2013601 (2023).","journal-title":"Nature"},{"key":"9868_CR64","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1259530","volume":"346","author":"CJ Russo","year":"2014","unstructured":"Russo, C. J. & Passmore, L. A. Ultrastable gold substrates for electron cryomicroscopy. Science 346, 1377\u20131380 (2014).","journal-title":"Science"},{"key":"9868_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsb.2005.03.010","volume":"151","author":"C Suloway","year":"2005","unstructured":"Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41\u201360 (2005).","journal-title":"J. Struct. Biol."},{"key":"9868_CR66","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41592-019-0580-y","volume":"16","author":"D Tegunov","year":"2019","unstructured":"Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146\u20131152 (2019).","journal-title":"Nat. Methods"},{"key":"9868_CR67","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"9868_CR68","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41592-020-00990-8","volume":"17","author":"A Punjani","year":"2020","unstructured":"Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214\u20131221 (2020).","journal-title":"Nat. Methods"},{"key":"9868_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1107\/S205225251801463X","volume":"6","author":"J Zivanov","year":"2019","unstructured":"Zivanov, J., Nakane, T. & Scheres, S. H. W. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ 6, 5\u201317 (2019).","journal-title":"IUCrJ"},{"key":"9868_CR70","doi-asserted-by":"publisher","first-page":"e42166","DOI":"10.7554\/eLife.42166","volume":"7","author":"J Zivanov","year":"2018","unstructured":"Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).","journal-title":"eLife"},{"key":"9868_CR71","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","volume":"180","author":"SHW Scheres","year":"2012","unstructured":"Scheres, S. H. W. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519\u2013530 (2012).","journal-title":"J. Struct. Biol."},{"key":"9868_CR72","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jmb.2003.07.013","volume":"333","author":"PB Rosenthal","year":"2003","unstructured":"Rosenthal, P. B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333, 721\u2013745 (2003).","journal-title":"J. Mol. Biol."},{"key":"9868_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ultramic.2013.06.004","volume":"135","author":"S Chen","year":"2013","unstructured":"Chen, S. et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24\u201335 (2013).","journal-title":"Ultramicroscopy"},{"key":"9868_CR74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"9868_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"9868_CR76","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"9868_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.str.2018.09.006","volume":"27","author":"B Frenz","year":"2019","unstructured":"Frenz, B. et al. Automatically fixing errors in glycoprotein structures with Rosetta. Structure 27, 134\u2013139 (2019).","journal-title":"Structure"},{"key":"9868_CR78","doi-asserted-by":"publisher","first-page":"e17219","DOI":"10.7554\/eLife.17219","volume":"5","author":"RY-R Wang","year":"2016","unstructured":"Wang, R. Y.-R. et al. Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. eLife 5, e17219 (2016).","journal-title":"eLife"},{"key":"9868_CR79","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. Struct. Biol. 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. Struct. Biol."},{"key":"9868_CR80","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"9868_CR81","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"9868_CR82","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00065-21","volume":"12","author":"A Addetia","year":"2021","unstructured":"Addetia, A. et al. SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98. mBio 12, e00065-21 (2021).","journal-title":"mBio"},{"key":"9868_CR83","doi-asserted-by":"publisher","first-page":"e02107","DOI":"10.1128\/JCM.02107-20","volume":"58","author":"A Addetia","year":"2020","unstructured":"Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 58, e02107\u2013e02120 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"9868_CR84","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"9868_CR85","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","volume":"28","author":"M Kearse","year":"2012","unstructured":"Kearse, M. et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28, 1647\u20131649 (2012).","journal-title":"Bioinformatics"},{"key":"9868_CR86","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pbiomolbio.2019.09.002","volume":"150","author":"PR Baldwin","year":"2020","unstructured":"Baldwin, P. R. & Lyumkis, D. Non-uniformity of projection distributions attenuates resolution in Cryo-EM. Prog. Biophys. Mol. Biol. 150, 160\u2013183 (2020).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"9868_CR87","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/pro.3779","volume":"29","author":"A Ben Chorin","year":"2020","unstructured":"Ben Chorin, A. et al. ConSurf-DB: an accessible repository for the evolutionary conservation patterns of the majority of PDB proteins. Protein Sci. 29, 258\u2013267 (2020).","journal-title":"Protein Sci."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09868-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:03:18Z","timestamp":1770818598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09868-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":87,"journal-issue":{"issue":"8101","published-print":{"date-parts":[[2026,2,12]]}},"alternative-id":["9868"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09868-1","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.P., B.P., A.D., K.C., A.B., D.C. and F.B. are employees of Vir Biotechnology and may hold shares. Vir Biotechnology (L.P., D.C. and F.B.) and the University of Washington (A.A. and D.V.) filed a provisional patent application describing these results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}